The Wistar Institute Of Anatomy And Biology

The Wistar Institute Of Anatomy And Biology, a tax-exempt nonprofit biomedical research organization headquartered in Philadelphia, Pennsylvania, acts as a prime recipient of federal research grants, particularly from the National Institutes of Health (NIH), to conduct hypothesis-driven basic and translational biomedical research in cancer immunology, HIV immunotherapy, vaccine development, and molecular biology.

The Institute's federal funding footprint centers on NIH grants, which dominate its award portfolio. Among NIH components, the National Cancer Institute (NCI) funds 98 awards, the National Institute of Allergy and Infectious Diseases (NIAID) funds 43 awards worth $25 million combined potential value, and the National Institute of General Medical Sciences (NIGMS) funds numerous basic research projects. The Defense Health Agency (DHA) has emerged as a significant secondary customer, funding 14 awards predominantly in military-relevant cancer immunotherapy and melanoma research. The Defense Advanced Research Projects Agency (DARPA) leads in potential value among smaller customer sets, with three awards valued at $26.9 million. Top customers by award count account for 74% of awards; the concentration across the NIH and DHA systems reflects the Institute's specialization in federally-funded basic research.

Representative research deliverables span multiple therapeutic domains. On cancer immunotherapy, Wistar received a $651,940 NCI Project Grant (through April 2031) for fundamental research elucidating targetable mechanisms sustaining immunosuppressive neutrophils in the glioblastoma tumor microenvironment, and a $780,764 NCI award (through March 2031) investigating branched-chain amino acid oxidation in tumor-associated macrophages to enhance anti-tumor immunity in pancreatic ductal adenocarcinoma. On HIV cure strategies, NIAID funded a $3.57 million Cooperative Agreement (through May 2030) to develop an individualized HIV cure strategy targeting autologous neutralizing antibody-resistant HIV reservoirs through combined immunotherapy including messenger RNA–lipid nanoparticle technology, engineered natural killer cells, and CAR T cells; a related $506,550 NIAID Project Grant (through May 2028) focused on neutralizing persistent Type-I Interferon signaling to improve HIV-specific CAR T cell therapy. On vaccine development, NIAID awarded a $887,239 Project Grant (through April 2031) to redirect antibody epitope specificity for HIV-1 vaccine advancement and funded a $3.57 million cooperative agreement titled "Individualized HIV Curative Combination Strategy Against Persistent HIV on ART," with Duke University as a sub-awardee providing computational envelope sequence analysis and vaccine design optimization. The DHA funded a $1.1 million Project Grant (through September 2028) on immunotherapeutic targeting of SLC39A9 in CDKN2A-low melanoma, with a University of Pennsylvania sub-award of $137,825 for inductively coupled plasma mass spectrometry analysis of zinc biomarkers. NIGMS funded a $591,549 Project Grant (through March 2031) investigating transcriptional integrity control through the Integrator complex and PP2A phosphatase and a $506,550 award (through January 2031) on compartmentalization and discrimination of double-stranded RNA in the nucleus.

The Institute acts as prime recipient on 81% of awards (274 of 337 total), with 19% as subcontractor on grants led by other institutions. In its subcontractor role, Wistar delivers specialized research services to Duke University on HIV cure strategy development, to the University of Pennsylvania on humanized mouse model generation and proteomics analysis for melanoma immunotherapy, and to multiple collaborating institutions on vaccine development and computational biology tasks. Federal grant activity has grown from 8 awards in 2023 to 34 in 2024 and 32 in 2025, with 20 awards placed or obligated year-to-date in 2026. Within the next twenty-four months, 33 awards reach ultimate completion, creating recompete opportunity across cancer treatment research, HIV immunotherapy, and vaccine programs. Service Contract Inventory data shows minimal SCI-reportable activity, reflecting the Institute's focus on research grants rather than federal service contracts; SCI records span three sub-award engagements with roughly 1.5 FTEs delivered across FY2022–FY2024, indicating that most Wistar work flows through grant mechanisms rather than SCI-reportable service arrangements.